Analyst Coverage Initiated Stock
Report Date: 02-20-2024
Symbol: CGON - CG Oncology, Inc. Common stock
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: CGON rating Overweight by Morgan Stanley
Price Target: $55
CG Oncology, Inc. Common stock (CGON)
,
Phone:
Website:
CEO:
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.